Detalhe da pesquisa
1.
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Gastroenterology
; 158(8): 2180-2194, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32147484
2.
Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy.
J Viral Hepat
; 28(5): 817-825, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33556206
3.
HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.
Hepatol Commun
; 6(8): 1870-1880, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35368148
4.
Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
Hepatol Commun
; 5(2): 189-202, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33553968
5.
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Hepatol Commun
; 5(11): 1873-1887, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34558823
6.
Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg.
Sci Rep
; 10(1): 7837, 2020 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32398799
7.
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Lancet Gastroenterol Hepatol
; 2(12): 877-889, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28964701